{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:20Z","timestamp":1790217380411,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to report the treatment outcomes of early and deferred laser in infants of aggressive posterior retinopathy of prematurity (APROP) after initial treatment with intravitreal Ranibizumab (IVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In a prospective, randomized, interventional study, infants with APROP received IVR (0.25 mg) and were randomized into two groups prior to laser. Laser was done at 1 week (group 1) or at 6 weeks or earlier if there was a recurrence of plus disease (group 2). The structural outcome, number of laser spots, duration of laser procedure and refractive error at 6 months were compared. Favorable structural outcome was defined as, complete regression of disease at 6 weeks after laser.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      63 eyes of 32 infants with APROP were enrolled. Mean gestational age (GA) and birth weight (BW) were 30.2\n                      <jats:bold>\u00b1<\/jats:bold>\n                      2.3 weeks and 1294\n                      <jats:bold>\u00b1<\/jats:bold>\n                      372.8 grams respectively. GA, BW, and disease severity were comparable at baseline. 27 (90%) eyes in group 1 and 29 (93.5%) eyes in group 2 had favorable structural outcome (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.61) at 6 weeks after laser. Eyes in group 2 (2149.8 \u00b1 688.7) required lesser number of laser spots than group 1 (2570.8 \u00b1 615) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). At six months, more eyes in group 1 had myopic refractive error (Mean spherical equivalent: \u20131.0D \u00b1 1.3) than those in group 2 (Mean spherical equivalent: 0.5D \u00b1 1.9) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Infants with APROP receiving IVR have comparable structural outcomes after an early or deferred laser. Moreover, eyes undergoing deferred laser require less number of laser spots and have a less myopia at 6 months after laser.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_3016_20","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:22:48Z","timestamp":1627899768000},"page":"2171-2176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity"],"prefix":"10.4103","volume":"69","author":[{"given":"Anil Babanrao","family":"Gangwe","sequence":"first","affiliation":[{"name":"Consultant Vitreo Retina Services, Vitreoretina Services, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Director, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish Kumar","family":"Gangrade","sequence":"additional","affiliation":[{"name":"DNB Trainee, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil Madhukar","family":"Parchand","sequence":"additional","affiliation":[{"name":"Consultant Vitreo Retina Services, Vitreoretina Services, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepanshu","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Consultant Vitreo Retina Services, Vitreoretina Services, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Vardhan","family":"Azad","sequence":"additional","affiliation":[{"name":"Professor of Ophthalmology, Regional Institute of Ophthalmology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4103\/0301-4738.128639","article-title":"Aggressive posterior retinopathy of prematurity in infants\u22651500 g birth weight","volume":"62","author":"Sanghi","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12098-009-0175-1","article-title":"Severe retinopathy of prematurity in big babies in India:History repeating itself?","volume":"76","author":"Shah","year":"2009","journal-title":"Indian J Pediatr"},{"key":"B5-20240828","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/eye.2017.18","article-title":"Characteristic clinical features associated with aggressive posterior retinopathy of prematurity","volume":"31","author":"Ahn","year":"2017","journal-title":"Eye (Lond)"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","article-title":"Aggressive posterior retinopathy of prematurity in Asian Indian babies:Spectrum of disease and outcome after laser treatment","volume":"29","author":"Sanghi","year":"2009","journal-title":"Retina"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","article-title":"Aggressive posterior retinopathy of prematurity:Risk factors for retinal detachment despite confluent laser photocoagulation","volume":"155","author":"Sanghi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0301-4738.86306","article-title":"Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes","volume":"59","author":"Katoch","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity:A report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","article-title":"Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Ar\u00e1mbulo","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2017.09.021","article-title":"Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity","volume":"2","author":"Tandon","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity:Comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/EB.S98715","article-title":"Impact of improved neonatal care on the profile of retinopathy of prematurity in rural neonatal centers in India over a 4-year period","volume":"8","author":"Vinekar","year":"2016","journal-title":"Eye Brain"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity:Clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity:A comparison study between ranibizumab and bevacizumab","volume":"236","author":"lyama\u00e7Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcjo.2018.03.005","article-title":"Posterior zone I retinopathy of prematurity:Spectrum of disease and outcome after laser treatment","volume":"54","author":"Katoch","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IAE.0b013e3181cafc30","article-title":"Do platelets have a role in the pathogenesis of aggressive posterior retinopathy of prematurity?","volume":"30","author":"Vinekar","year":"2010","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3016_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:19Z","timestamp":1786735819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3016_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3016_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2020-09-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}